Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Closed Loop Glucose Control in a Simulated ICU Setting

9. června 2026 aktualizováno: Ideal Medical Technologies

Demonstration of an Expert Rule-Based Automated Insulin Delivery (AID) System for People With Type 1 and Type 2 Diabetes

This is a proof of concept safety study of a rule-based closed loop glucose control system designed for use in the intensive care unit setting.

The persons with type 1 and type 2 diabetes in this study will have their glucose controlled to a range of 100-140 mg/dL by a fully autonomous novel rule-based closed loop glucose control system for a period of 24 hours. The subjects will consume three standardized meals and receive a continuous intravenous infusion of dextrose (D-glucose) during the 24 hour study period. Meals will not be announced to the glucose control system.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Tight glucose control in the intensive care unit (ICU) setting is difficult to achieve. The investigators hypothesize that a closed loop glucose control system that is rule-based will improve upon the glucose control currently achieved by the current open loop manual methods, and that this improved glucose control may improve the outcomes of critically ill patients.

This Earl Feasibility Study will test the ability of a prototype rule-based closed loop glucose control system named FUSION, to provide safe and effective glucose control in subjects with type 1 and type 2 diabetes in a clinical research center (CRC) setting. Subjects with type 1 diabetes have been chosen as safe and effective glucose control is difficult to achieve in these subjects during meal challenges. Subjects with type 2 diabetes have been chosen as they are insulin resistant, which makes their insulin resistance profile similar to that of ICU patients. As this is a safety study of a new medical device, the controlled environment of the CRC is preferable to the less controlled environment of an ICU setting.

The prototype FUSION system to be used in this study will consist to two Dexcom G6 continuous glucose monitors (CGM), the rule-based glucose control software run on an all-in-one medical computer, and two syringe pumps. The prototype system is housed on a medical cart. Based on the average glucose value of the two Dexcom G6 CGM's, and the algorithms of the FUSION systems rule-based glucose control software, the FUSION system will make rate adjustments every 5-10 minutes to the intravenous infusion rates of short acting insulin (NovoLog) and dextrose (D10NS) under its control, in an attempt to keep the subjects glucose in the range of 100-140 mg/dL. The FUSION system only requires entry of the subjects study identification number and weight in kilograms to initiate the system.

For safety reasons, the subjects will have their blood glucose independently measured every 10-60 minutes on the point of care Nova StatStrip system, throughout the 24 hour study period.

The study has halting criteria to avoid recurrent instances of severe hypoglycemia (< 54 mg/dL).

The average of the two CGM's, that is used by the FUSION system for glucose control, will be used for statistical analysis.

Typ studie

Intervenční

Zápis (Odhadovaný)

6

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Participants with type 1 and type 2 diabetes are eligible to be included in the study only if they meet all the following criteria:

    1. Are 18-70 years of age, inclusive.
    2. Can understand and sign an informed consent, communicate with the investigator, and understand and comply with the protocol requirements.
    3. Have had a diagnosis of type 1 or type 2 diabetes for a period of at least 3 months.
    4. Use insulin injections at home for glucose control.
    5. Have a hemoglobin A1c (HbA1c) in the range of 7.0 - 10.0%.

    6. Have a hemoglobin in the range for sex:

      1. Females: 7-15.5 grams/dL.
      2. Males: 7-17.5 grams/dl.
    7. Have adequate venous access sites in upper extremities.
    8. Body weight between 40 - 150 kg.

Exclusion Criteria:

  1. Have participated in an interventional medical, surgical, or pharmaceutical study within 30 days of screening.
  2. Have a known hypersensitivity to any of the components of study treatment.
  3. Have skin disease/injury at Dexcom G6 CGM insertion site(s) that would prevent insertion of the CGM.
  4. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant.
  5. Have a medical condition that in the opinion of the investigator could affect study participation and/or personal well-being.

  6. Have a clinically significant history or presence of any of the following conditions:

    1. Hepatic failure or has alanine aminotransferase (ALT) greater than 3 times the upper limit of normal.
    2. Has an estimated GFR <30 ml/min/1.73 m2 or End Stage Kidney Disease on renal replacement therapy.
    3. Have congestive heart failure greater than class 1 on the NYHA classification system.
    4. Have a history of seizures.
    5. Have a history of cerebrovascular accident.
    6. Have a history of ischemic heart disease.

  7. For female subjects of potential childbearing age (age 18 to 55) they will be excluded if:

    1. Pregnant.
    2. Refuse to agree to a pregnancy test at the time of enrollment.
    3. Have a positive urine pregnancy test at the time of enrollment.
  8. Have a positive Influenza or COVID test within 14 days of visit 3.
  9. Have any viral lower respiratory related symptoms (e.g., cough, chest tightness, respiratory distress) in the 14-day period prior to visit 3.
  10. Have a known unprotected Influenza or COVID exposure in the 14-day period prior to visit 3.
  11. Are currently being treated with Hydroxyurea, a medication which may cause the Dexcom G6 CGM to produce glucose readings that are higher than the actual glucose value.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Studie bezpečnosti systému Fusion Uzavřené smyčky
Všechny subjekty budou ošetřeny systémem kontroly glukózy s uzavřenou smyčkou Fusion po dobu až 24 hodin
Přístroj: Systém kontroly glukózy s uzavřenou smyčkou FUSION
Systém FUSION bude použit ke kontrole glukózy subjektů v rozmezí 100-140 mg/dl. Data budou shromažďována po dobu až 24 hodin nebo po předčasném ukončení studijní relace.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Primary Safety Measure
Časové okno: From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time up to 24 hours
The percentage of all glucose values <70 mg/dL
From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time up to 24 hours
Primary Efficacy Measure
Časové okno: From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
The percentage of all glucose values within the glucose range of 70-180 mg/dL
From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percent of All Glucose Values Within Glucose Range <54 mg/dL
Časové okno: From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time of up to 24 hours
The percentage of all glucose values that are less than 54 mg/dL
From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time of up to 24 hours
Percent of All Glucose Values Within Glucose Range 54-69 mg/dL
Časové okno: From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of up to 24 hours.
The percentage of all glucose values that are within the glucose range of 54-69 mg/dL
From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of up to 24 hours.
Number of Hypoglycemic Events (<70 mg/dL)
Časové okno: From beginning of use of the FUSION System until end of use of the FUSION System, which will be a period of time of up to 24 hours.
The total number of hypoglycemic events less than 70 mg/dL as measured by a continuous series of glucose values less than 70 mg/dL for at least 15 minutes duration.
From beginning of use of the FUSION System until end of use of the FUSION System, which will be a period of time of up to 24 hours.
Percent of All Glucose Values Within Glucose Range 70-100 mg/dL
Časové okno: From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
The percentage of all glucose values within the glucose range of 70-100 mg/dL
From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
Percent of All Glucose Values Within Glucose Range 70-140 mg/dL
Časové okno: From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
The percentage of all glucose values within the glucose range of 70-140 mg/dL
From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
Percent of All Glucose Values Within Glucose Range 100-140 mg/dL
Časové okno: From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
The percentage of all glucose values within the glucose range of 100-140 mg/dL
From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
Percent of All Glucose Values Within Glucose Range >140 mg/dL
Časové okno: From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
The percentage of all glucose values greater than 140 mg/dL
From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
Percent of All Glucose Values Within Glucose Range >180 mg/dL
Časové okno: From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time of up to 24 hours
The percentage of all glucose values that are greater than 180 mg/dL
From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time of up to 24 hours
Percent of All Glucose Values Within Glucose Range >250 mg/dL
Časové okno: From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time of up to 24 hours
The percentage of all glucose values that are greater than 250 mg/dL
From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time of up to 24 hours
Average glucose value in mg/dL
Časové okno: From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time of up to 24 hours
The average of all measured glucose values in mg/dL
From beginning of use of the FUSION System to end of use of the FUSION System, which will be a period of time of up to 24 hours
Measure of dispersion - Coefficient of Variation
Časové okno: From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
The Coefficient of variation of glucose will be calculated by dividing the standard deviation of the average glucose value by the average glucose value, then multiplying this value by 100.
From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
Clarke Error Grid Analysis of Continuous Glucose Monitor Data
Časové okno: From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
The study data will be used to determine the percentage of the two Dexcom G6 CGM's glucose values in each zone using a Clarke error grid analysis. This same calculation will be performed on the average of the two Dexcom G6 CGM systems used by the FUSION system for purposes of glucose control.
From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
FDA integrated Continuous Glucose Monitor Standards
Časové okno: From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
The study data will be used to determine if each individual Dexcom G6 CGM system, and their average value meet FDA criteria for integrated Continuous Glucose Monitor (iCGM) accuracy for the glucose zones <70 mg/dL, 70-180 mg/dL, and >180 mg/dL.
From beginning of use of FUSION System to end of use of FUSION System, which will be a period of time of up to 24 hours
Hemoglobin A1c Percentage Level
Časové okno: As measured from a blood draw within two weeks prior to the start of the 24-hour closed loop glucose control session
The subjects hemoglobin A1c measurement from a blood draw taken within 2 weeks of the start of the closed loop glucose control session
As measured from a blood draw within two weeks prior to the start of the 24-hour closed loop glucose control session
C-Peptide Level
Časové okno: As measured from a blood draw within two weeks prior to the start of the 24-hour closed loop glucose control session
The subjects C-peptide level will be measured prior to the start of the closed loop glucose control session.
As measured from a blood draw within two weeks prior to the start of the 24-hour closed loop glucose control session
Total Daily Dose of Insulin in Units/Kilogram
Časové okno: As documented within two weeks prior to the start of the 24-hour closed loop glucose control session
The subjects total daily dose of insulin used prior to the start of the closed loop glucose control session was calculated by adding up all of the insulin doses used by the subjects (both short and long acting insulin) in units and dividing this value by the subjects weight in Kilograms
As documented within two weeks prior to the start of the 24-hour closed loop glucose control session
Weight in Kilograms
Časové okno: As measured just prior to the start of the 24-hour closed loop glucose control session
Average weight in kilograms of the subjects
As measured just prior to the start of the 24-hour closed loop glucose control session
Body Mass Index
Časové okno: As measured just prior to the start of the 24-hour closed loop glucose control session
The body mass index will be calculated by dividing the subjects weight in kilograms by the square of their height in meters
As measured just prior to the start of the 24-hour closed loop glucose control session

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Ideal Medical Technologies

Spolupracovníci

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Emory University

Vyšetřovatelé

  • Ředitel studie: Leon M DeJournett, MD, Ideal Medical Technologies
  • Vrchní vyšetřovatel: Francisco Pasquel, MD, MPH, Emory School of Medicine

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. července 2026

Primární dokončení (Odhadovaný)

1. prosince 2026

Dokončení studie (Odhadovaný)

1. prosince 2027

Termíny zápisu do studia

První předloženo

9. června 2026

První předloženo, které splnilo kritéria kontroly kvality

9. června 2026

První zveřejněno (Aktuální)

12. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

12. června 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

9. června 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 2025P013846
  • 5R44DK133084-02 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Diabetes typu 1

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Ecuador

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit